Trial Profile
A Phase 1b/2 Study of Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Alvelestat (Primary)
- Indications Bronchiolitis obliterans; Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 17 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.
- 17 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Dec 2024.
- 01 Sep 2022 Planned End Date changed from 31 Dec 2022 to 1 Jan 2024.